{"schema_version":"secwatch.filing_event.v1","accession":"0001601485-25-000006","form_type":"8-K","ticker":"ELTX","cik":"0001601485","company_name":"Elicio Therapeutics, Inc.","filed_at":"2025-01-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.152072+00:00","generated_at":"2026-05-27T19:31:30.498677+00:00","sec_items":["8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Elicio receives supportive FDA feedback on ELI-002 Phase 3 registrational strategy","bullets":["FDA aligned on Phase 3 study design: dose, schedule, patient population (KRAS-mutated pancreatic cancer), and DFS endpoint.","Phase 2 AMPLIFY-7P study fully enrolled; interim DFS analysis expected H1 2025.","Positive Phase 2 results could support rapid advancement into Phase 3 and potential BLA filing.","ELI-002 is an off-the-shelf monotherapy for mKRAS cancers patients post-chemotherapy."],"urls":{"canonical":"https://secwatch.observer/filing/0001601485-25-000006","json":"https://secwatch.observer/filing/0001601485-25-000006.json","markdown":"https://secwatch.observer/filing/0001601485-25-000006.md","text":"https://secwatch.observer/filing/0001601485-25-000006.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1601485/000160148525000006/0001601485-25-000006-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1601485/000160148525000006/angn-20250122.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-27T19:31:30.498677+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}